AXT, Inc. (AXTI) Q4 2025 earnings review
AI Demand Meets Bureaucratic Wall
AXT's narrative is a clash between a massive technological tailwind and a geopolitical chokehold. While management touts an AI-driven 'tsunami' of demand for Indium Phosphide (InP), Q4 revenue fell 18% sequentially to $23.0M and dropped 8% YoY, primarily because China didn't issue enough export permits. The company remains loss-making (-$2.3M Non-GAAP), though margins have stabilized in the low-20s after the Q1 disaster. A massive capital raise in December spiked cash to $120M, buying time, but until the permit process becomes predictable, the AI growth story remains stuck in customs.
🐂 Bull Case
The balance sheet has been transformed. Cash and equivalents surged to $120.3M (up from $22.8M a year ago) following a December capital raise. This removes immediate liquidity concerns and funds the planned doubling of InP capacity.
The underlying demand driver—Indium Phosphide for AI data center connectivity—is real. Management cites new Tier-1 customer engagements and expects sequential growth in 26Q1 as permits arrive.
🐻 Bear Case
Revenue is now a function of Chinese bureaucracy, not customer demand. The sequential drop from $28M to $23M proves that permit issuance is volatile and opaque. You cannot reliably model growth when the supply chain is politically gated.
Despite the hype, the company has posted Non-GAAP net losses for five consecutive quarters. Even with the margin recovery to 21.5%, the business model is currently failing to cover its operating base.
⚖️ Verdict: 🔴
Bearish. The $120M cash pile puts a floor under the stock, but the core business is paralyzed by export controls. Until AXT demonstrates consistent ability to ship what it sells, the 'AI Tsunami' narrative is just noise.
Key Themes
Export Permits: The Chokehold
The primary reason for the Q4 revenue miss (dropping to $23M from $28M in Q3) was the failure to receive expected export permits from China. While management claims to have received 'some' permits for 2026, the process remains the single biggest risk factor. The company is effectively unable to control its own shipping schedule.
Gross Margin Recovery Stabilizing
After the catastrophic -6.1% margin in 25Q1 (caused by yield issues), the company has successfully stabilized manufacturing. Non-GAAP gross margin held at 21.5% in Q4, slightly down from 22.4% in Q3 but vastly improved from the first half of the year. This suggests the yield issues are largely resolved.
Massive Liquidity Injection
A December capital raise radically altered the balance sheet. Ending cash is $120.3M, up ~5x from $22.8M a year ago. This dilution funds the strategy to 'double indium phosphide manufacturing capacity' in 2026 and insulates the company from short-term burn rates.
Capacity Expansion for AI
Despite current shipping constraints, AXT is doubling down. Management confirmed they are on track to double Indium Phosphide (InP) capacity in 2026 to support the 'AI infrastructure build-out.' This indicates high confidence in long-term demand, specifically for high-speed optical interconnects.
Tongmei IPO Stalls
The listing of subsidiary Tongmei on the Shanghai STAR Market remains 'subject to review.' This narrative has persisted for quarters with the timeline shifting from 'coming months' repeatedly. Given the geopolitical tensions, investors should assign low probability to a near-term liquidity event here.
Other KPIs
Remains in the red, deteriorating from -$1.2M in Q3. While an improvement over the -$4.3M loss in 24Q4, the company has failed to reach breakeven despite the margin recovery, driven by lower revenue volume.
Stable YoY ($85M in 24Q4). The company is carrying significant inventory relative to sales (3.5x quarterly revenue), likely building stock in anticipation of export permits. This is a risk if technology transitions render stock obsolete.
Decelerating. Down 11% from $99.4M in FY24. The combination of yield issues in H1 and permit issues in H2 made 2025 a lost year for growth.
Guidance
Accelerating. Management 'believes we are in a strong position to achieve sequential revenue growth in Q1.' No specific range provided in the release, but implies >$23M. The driver is explicitly 'growth in indium phosphide' and receipt of new permits.
Key Questions
Permit Velocity
You mentioned receiving 'some' permits for 2026. What percentage of your Q1 revenue guidance is covered by permits already in hand versus permits you hope to receive?
Capital Allocation
With the cash balance exploding to $120M, how much is earmarked for the InP capacity expansion versus general working capital burn? Is there an acquisition strategy?
Customer Attrition
With Q4 shipments delayed by permits, have you seen any evidence of Tier-1 customers dual-sourcing or shifting share to competitors who don't face these export restrictions?